EA treatment increased the protein levels of DRP1 and MFN1 in the prostate of TP-treated BPH rats while the levels of ATP5A, MTCO, and SDHB were decreased by EA in the tissue (Fig. 3A, B). The gene discussed is MFN1; the disease is benign prostatic hyperplasia.